| Literature DB >> 26645669 |
Tina Deihim1,2, Parisa Amiri3, Reza Taherian1,2, Maryam Tohidi4, Asghar Ghasemi5, Leila Cheraghi1, Fereidoun Azizi6.
Abstract
BACKGROUND: The superiority of the diagnostic power of different definitions of metabolic syndrome (MetS) in detecting objective and subjective cardiovascular outcomes is under debate. We sought to compare diagnostic values of different insulin resistance (IR)-based definitions of MetS in detecting poor health-related quality of life (HRQoL) in a large sample of Tehranian adults.Entities:
Mesh:
Year: 2015 PMID: 26645669 PMCID: PMC4673768 DOI: 10.1186/s12955-015-0391-5
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Different definitions and their cut-offs used to define the metabolic syndrome
| World Health Organization (WHO) | European Group for the study of Insulin Resistance (EGIR) | American Association of Clinical Endocrinology (AACE) | |
|---|---|---|---|
| Absolutely required | IGTa or IFGb or IRc or diabetes | Plasma insulin > 75 percentile of persons without diabetes in the population under study. | High risk of being insulin resistant d (excluding diabetes) |
| Criteria | plus two or more of the below abnormalities | plus two or more of the four below abnormalities | Plus two or more of the four below abnormalities |
| Adiposity index | WHR > 0.90 in men and >0.85 in women and/or BMI > 30 kg/m2 | WC ≥ 94 cm in men and ≥80 cm in women | none |
| Triglycerides | ≥1.7 mmol/L and/or | >2 mmol/L and/or | >1.7 mmol/L |
| HDL | <0.9 mmol/L in men and <1.0 mmol/L in women | <1.0 mmol/L or treated for dyslipidemia | <1.0 mmol/L in men and <1.3 mmol/L in women. |
| Blood pressure | ≥140/90 mmHg or treated for hypertension | ≥140/90 mmHg or treated for hypertension | ≥130/85 mmHg or treated for hypertension |
| Hyperglycemia | none | Fasting plasma glocuse ≥ 6.1 mmol/L (but without diabetes) | Fasting plasma glucose 6.1–6.9 mmol/L or IGT |
BMI, body mass index; WC, waist circumference; IGT, impaired glucose tolerance; IFG, impaired fasting glucose; HDL, high density lipoprotein; WHR, waist to hip ratio a120 min post glucose challenge (75 mg):7.8–11.1 mm/L bFasting plasma glucose 5.6–7.00 mm/L cdefined as plasma insulin > 75 percentile of persons without diabetes in the population under study dFor the AACE definition, high risk of being insulin resistant is indicated by the presence of at least one of the followings: diagnosis of hypertension or cardiovascular disease; family history of type 2 diabetes or history of gestational diabetes or glucose intolerance; BMI > 25 kg/m2 or WC > 94 cm (men), >80 cm (women); age >40 years
General characteristics of study participants
| All ( | Men ( | Women ( | P-value | |
|---|---|---|---|---|
| Age (y) | 49.78 (13.25) | 51.25 (14.13) | 49.06 (12.75) | 0.04 |
| Education (%) | <0.001 | |||
|
| 358 (49.1) | 80 (33.2) | 278 (57.0) | |
|
| 265 (36.4) | 104 (43.2) | 161 (33.0) | |
|
| 106 (14.5) | 57 (23.7) | 49 (10.0) | |
| Marital status (%) | <0.001 | |||
|
| 632 (85.2) | 226 (91.9) | 406 (81.9) | |
|
| 110 (14.8) | 20 (8.1) | 90 (18.1) | |
| Smoking (%) | <0.001 | |||
|
| 46 (6.3) | 41 (17.0) | 5 (1.0) | |
|
| 680 (93.7) | 200 (83.0) | 480 (99.0) | |
| MET-h/wk | 22.1 (7.7–58.1) | 23.3 (7.9–63.1) | 20.3 (7.6–57.5) | 0.80 |
| WHR | 0.9 (0.1) | 1.0 (0.1) | 0.9 (0.1) | <0.001 |
| WC (cm) | 95.3 (11.6) | 98.1 (10.2) | 93.9 (12.0) | <0.001 |
| BMI (kg/m2) | 29.1 (4.7) | 27.8 (4.4) | 29.7 (4.8) | <0.001 |
| TG (mmol/L) | 1.8 (1.3–2.5) | 1.9 (1.3–2.7) | 1.8 (1.2–2.4) | 0.10 |
| Total cholesterol (mmol/L) | 5.2 (1.0) | 5.1 (0.9) | 5.3 (1.0) | <0.001 |
| HDL-C (mmol/L) | 1.1 (0.3) | 1.0 (0.2) | 1.1 (0.3) | <0.001 |
| LDL-C (mmol/L) | 3.3 (0.8) | 3.2 (0.8) | 3.3 (0.9) | 0.11 |
| FBS (mmol/L) | 5.7 (1.9) | 5.8 (1.8) | 5.7 (2.0) | 0.32 |
| BS2hr (mmol/L) | 6.5 (2.7) | 6.2 (2.5) | 6.6 (2.8) | 0.07 |
| SBP (mmHg) | 120.2 (19.0) | 124.0 (16.7) | 118.3 (19.8) | <0.001 |
| DBP (mmHg) | 75.1 (10.1) | 77.0 (10.0) | 74.2 (10.1) | <0.001 |
| Menopause (%) | - | - | 165 (34.3) | - |
| Pre-diabetes (%) | 150 (20.7) | 51 (21.2) | 99 (20.5) | 0.80 |
| Metabolic Syndrome (%) | ||||
| WHO | 302 (41.8) | 107 (44.2) | 195 (40.6) | 0.36 |
| aEGIR | 149 (25.6) | 49 (25.8) | 100 (25.5) | 0.94 |
| aAACE | 179 (30.7) | 62 (33.2) | 117 (29.5) | 0.37 |
Data represented as mean (SD) for continuous variables with normal distribution and median (25 percentile-75 percentile) for continuous variables with non-normal distribution or n (%) for categorically distributed variables
P-values according to independent sample t-test, χ2-test and Mann–Whitney test between genders
BMI, body mass index; WC, waist circumference; IGT, impaired glucose tolerance; IFG, impaired fasting glucose; HDL, high density lipoprotein; WHR, waist to hip ratio; WHO, World Health Organization; EGIR, European Group for the study of Insulin Resistance; AACE, American Association of Clinical Endocrinology
a The number of study participants for EGIR and AACE definitions is 590
Scores of the 36-item Short Form health survey (SF-36), according to different definitions of the metabolic syndrome in men and women
| WHO | EGIR | AACE | |
|---|---|---|---|
| Men | |||
| Physical functioning | 79.4 (45.3) | 79.2 (47.3) | 76.5 (45.8)** |
| Role physical | 68.3 (83.1) | 69.2 (89.2) | 62.3 (87.5) |
| Bodily pain | 73.2 (45.9) | 73.2 (49.5) | 69.6 (48.7) |
| General health | 66.4 (49.1) | 65.0 (52.2) | 64.4 (51.0) |
| Vitality | 68.9 (47.1) | 69.7 (51.4) | 68.9 (50.3) |
| Social functioning | 77.5 (59.9) | 72.7 (66.4) | 75.1 (65.2) |
| Role emotional | 58.2 (102.4) | 48.5 (107.1) | 53.5 (104.9) |
| Mental health | 73.1 (46.7) | 71.3 (52.1) | 74.7 (51.1) |
| PCS | 71.8 (41.9) | 71.6 (43.5) | 68.2 (42.4) |
| MCS | 69.4 (50.3) | 65.6 (53.7) | 68.1 (52.6) |
| Women | |||
| Physical functioning | 76.7 (46.4) | 76.4 (53.0) | 72.9 (49.5)* |
| Role physical | 63.2 (75.8) | 69.2 (86.8) | 68.1 (81.3) |
| Bodily pain | 70.3 (43.2) | 69.6 (48.5) | 70.1 (45.2) |
| General health | 64.5 (39.5) | 65.9 (44.5) | 64.3 (41.7) |
| Vitality | 59.8 (43.4) | 60.7 (50.3) | 58.7 (46.8) |
| Social functioning | 74.4 (49.0) | 76.2 (56.1) | 72.4 (52.3) |
| Role emotional | 65.9 (81.2) | 66.8 (93.4) | 67.4 (86.8) |
| Mental health | 66.7 (41.0) | 65.8 (47.2) | 64.1 (43.6) |
| PCS | 68.7 (38.6) | 70.3 (44.1) | 68.9 (41.3) |
| MCS | 66.7 (42.1) | 67.4 (48.3) | 65.6 (45.2) |
Data represented as mean (SD)
WHO, World Health Organization; EGIR, European Group for the study of Insulin Resistance; AACE, American Association of Clinical Endocrinology; PCS, physical component summary; MCS, mental component summary
* 0.05 ≤ p ≤ 0.07 for poor health-related quality of life which is not significant in α = 0.05 but is significant in α = 0.10
** P < 0.05 for poor health-related quality of life
Odds ratio (95 % CI) and area under the curve (AUC) for poor physical and mental HRQoL according to different definitions of metabolic syndrome
| WHO | EGIR | AACE | |
|---|---|---|---|
| Physical component summary (PCS) | |||
| Men | |||
| Number of individuals with MetS and poor HRQoL(%) | 37 (34.6) | 16 (32.7) | 24 (38.7) |
| Adjusted Odds ratio (95 % CI) | |||
| Model 1 | 1.89 (1.00–3.57)** | 2.04 (0.83–5.03) | 1.75 (0.82–3.71) |
| Model 2 | 1.83 (0.96–3.49)* | 2.05 (0.83–5.07) | 1.72 (0.77–3.84) |
| Model 3 | 1.72 (0.88–3.35) | 1.80 (0.69–4.69) | 1.95 (0.84–4.53) |
| AUC | 0.64 (0.56–0.73) | 0.66 (0.56–0.75) | 0.66 (0.56–0.76) |
| Women | |||
| Number of individuals with MetS and poor HRQoL | 70 (35.9) | 30 (30) | 46 (39.3) |
| Adjusted Odds ratio (95 % CI) | |||
| Model 1 | 1.51 (0.97–2.37)* | 1.21 (0.67–2.19) | 1.56 (0.92–2.64) |
| Model 2 | 1.08 (0.67–1.75) | 1.06 (0.57–1.96) | 0.98 (0.55–1.76) |
| Model 3 | 0.96 (0.57–1.60) | 0.93 (0.48–1.81) | 1.01 (0.55–1.85) |
| AUC | 0.73 (0.68–0.79) | 0.74 (0.67–0.80) | 0.73 (0.67–0.79) |
| Mental component summary (MCS) | |||
| Men | |||
| Number of individuals with MetS and poor HRQoL(%) | 33 (30.8) | 17 (34.7) | 18 (29) |
| Adjusted Odds ratio (95 % CI) | |||
| Model 1 | 0.92 (0.49–1.73) | 1.16 (0.52–2.59) | 0.74 (0.35–1.58) |
| Model 2 | 0.95 (0.50–1.80) | 1.17 (0.52–2.62) | 0.80 (0.36–1.81) |
| Model 3 | 0.75 (0.37–1.49) | 0.93 (0.38–2.23) | 0.97 (0.41–2.28) |
| AUC | 0.63 (0.54–0.71) | 0.65 (0.55–0.75) | 0.65 (0.55–0.74) |
| Women | |||
| Number of individuals with MetS and poor HRQoL(%) | 71 (36.4) | 36 (36) | 43 (36.8) |
| Adjusted Odds ratio (95 % CI) | |||
| Model 1 | 1.14 (0.73–1.77) | 1.15 (0.66–1.99) | 1.25 (0.74–2.12) |
| Model 2 | 1.00 (0.63–1.58) | 1.07 (0.61–1.88) | 1.01 (0.57–1.77) |
| Model 3 | 0.89 (0.55–1.45) | 0.97 (0.54–1.74) | 1.00 (0.56–1.79) |
| AUC | 0.65 (0.59–0.71) | 0.66 (0.59–0.73) | 0.65 (0.59–0.72) |
WHO, World Health Organization; EGIR, European Group for the study of Insulin Resistance; AACE, American Association of Clinical Endocrinology; HRQoL, Health related quality of life
Model 1: Unadjusted, Model 2: Adjusted for age, Model 3: Adjusted for age, smoking (only in men) (Ref: Never or ex-smoking), education (Ref: Above high school education), marital status (Ref: Married) and menopause (Ref: reproductive age)
* 0.05 ≤ p ≤ 0.07 for poor health-related quality of life
** P < 0.05 for poor health-related quality of life